Enhancement of the neonate's nonspecific immunity to Klebsiella infection by muramyl dipeptide, a synthetic immunoadjuvant.
N-acetylmuramyl-L-alanyl-D-isoglutamine (muramyl dipeptide) and certain derivatives that are structural analogs of part of the bacterial peptidoglycan monomer have been shown to be adjuvant active and to enhance the nonspecific immunity of adult mice infected by Klebsiella pneumoniae. In the present study muramyl dipeptide and two other synthetic analogs were found to be active in newborn mice. This activity could be demonstrated after administration by subcutaneous or even by oral route. In contrast to what was observed after treatment by lipopolysaccharide, 8-day-old mice were definitively protected against bacterial challenge by these glycopeptides. Therefore such molecules could have a great value in view of studying and correcting the neonate's unresponsiveness.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000315:Adrenalectomy; D000818:Animals; D000831:Animals, Newborn / Q000276:immunology*; D006020:Glycopeptides / Q000008:administration & dosage / Q000276:immunology*; D007113:Immunity, Innate; D007710:Klebsiella Infections / Q000276:immunology* / Q000517:prevention & control; D007711:Klebsiella pneumoniae / Q000276:immunology; D008070:Lipopolysaccharides / Q000276:immunology; D051379:Mice; D009112:Muramic Acids / Q000276:immunology; D010587:Phagocytosis
D000276:Adjuvants, Immunologic; D006020:Glycopeptides; D008070:Lipopolysaccharides; D009112:Muramic Acids